Hepatocellular carcinoma (HCC) remains a global health challenge with limited treatment
options and a poor prognosis for advanced-stage patients. Recent advancements in cancer …

The most typical type of liver cancer or hepatocellular carcinoma (HCC) develops from
hepatocyte loss. Non-alcoholic fatty liver disease (NAFLD), viral hepatitis C and cirrhosis are …

The roles of γδ T cells in liver cancer, especially in the potential function of immunotherapy
due to their direct cytotoxic effects on tumor cells and secretion of important cytokines and …

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. γδ T cells
have been revealed to be promising candidates for immunotherapy in patients with HCC …

The γδ T cell subset was discovered over 30 years ago, yet continues to be an exciting and
challenging component of the adaptive immune response. While γδ T cells represent a very …

In hepatocellular carcinoma (HCC), γδ T cells participate in mediating the anti‐tumour
response and are linked with a positive prognosis. However, these cells can become pro …

BACKGROUND & AIMS: The immunosuppressive network within the tumor
microenvironment is one of the major obstacles to the success of cancer immunotherapy. γδ …

Hepatocellular carcinoma (HCC) is the most common primary liver carcinoma and has one
of the highest mortality rates of all cancers. The γδ T cells could infiltrate HCC and have …

In recent years, the application of chimeric antigen receptor T-cell (CAR-T) therapy based on
gamma delta T (γδT) cells in hepatocellular carcinoma (HCC) immunotherapy has attracted …

Cancer immunotherapy is a field of interest in the recent treatment approaches against
cancer cells, as it could use the assets of the host's immune system against the invading …